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INTRODUCTION 
Aging is a multifactorial phenomenon that involves the 
accumulation of diverse metabolic changes and 
consequential damage at the cellular, tissue and 
organismal levels, resulting in functional losses and an 
increased probability of diseases [1].  
The klotho protein plays a critical role in regulating 
aging and the development of age-related diseases in 
mammals [2, 3]. Deficiency of klotho caused an 
extensive premature aging phenotype that manifested as 
osteoporosis, skin atrophy, ectopic calcification, 
impaired bone mineralization, neurodegeneration and a 
shortened life span. Conversely, klotho overexpression 
extended the life span and rescued aging disorders [2]. 
Recent studies have revealed that the membrane-bound 
form of klotho acts a coreceptor for fibroblast growth 
factor 23 (FGF23), which is required for the 
biosynthesis of vitamin D and phosphate reabsorption, 
whereas secreted klotho functions as a humoral factor in 
various intracellular signaling pathways [4, 5], 
including the insulin/insulin-like growth factor-1 
(insulin/IGF-1), protein kinase C, cAMP, p53/p21, 
transforming growth factor (TGF)-β1 and Wnt 
pathways [6, 7]. Klotho is also known to play an 
important role in renal function [8]. A previous report 
showed that klotho decreased apoptosis in renal failure, 
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ABSTRACT 
Aging is characterized by a reduced ability to defend against stress, an inability to maintain homeostasis, and an 
increased risk of disease. In this study, a metabolomics approach was used to identify novel metabolic 
pathways that are perturbed in a mouse model of accelerated aging (SAMP1/kl-/-) and to gain new insights into 
the metabolic associations of the metformin derivative HL156A. Extensive inflammation and calcification were 
observed in the tissues of the SAMP1/kl-/- mice with premature aging. In mouse embryonic fibroblasts (MEFs) 
obtained from SAMP1/kl-/- mice, we observed that HL156A induced FOXO1 expression through inhibition of 
the IGF-1/AKT/mTOR signaling pathways. Treatment of HL156A decreased reactive oxygen species production 
and enhanced mitochondrial transmembrane potential in SAMP1/kl-/- MEFs. A metabolomic profile analysis 
showed that HL156A increased the GSH/GSSG ratio in the kidneys of SAMP1/kl-/- mice (8-12 weeks old). In 
addition, treating SAMP1/kl-/- mice with HL156A (30 mg/kg) for 4 weeks improved survival and decreased the 
significant elevation of oxidized GSH (GSSG) that was observed in SAMP1/kl-/- mice. In histological sections, 
HL156A administered SAMP1/kl-/- mice exhibited a decrease in excessive calcification. Based on these findings, 
we conclude that the new metformin derivative HL156A may inhibit oxidative damage by inducing glutathione 
metabolism and antioxidant pathways. 
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including acute and chronic kidney disease, and its 
expression was strongly decreased in kidney injury due 
to various etiologies that mainly involved inflammation 
and aging [8, 9]. In addition, klotho deletion resulted in 
bone damage, suggesting that this protein is crucial for 
maintaining normal bone structure and formation [10]. 
Despite our growing understanding of klotho biology, 
numerous important questions regarding its properties 
and functions remain unanswered. 
Recently, metformin, an antidiabetic drug for type 2 
diabetes mellitus, has emerged as a successful and 
consistent pharmacological drug that exerts a protective 
effect against the age-associated deterioration of 
biological functions in addition to improving the 
lifespan [11]. This observation was also confirmed by 
the results of numerous meta-analyses of human data 
[12, 13]. Metformin acts by inducing the adenosine 
monophosphate-activated protein kinase (AMPK)-
dependent pathway to control the aging process and 
extend the lifespan [14,15]. Thus, there is an increasing 
amount of interest in searching for candidate drugs or 
derivatives that can mimic and elicit the beneficial 
effects of metformin on the lifespan, aging, and age-
associated diseases. The metformin derivative HL156A 
functions through similar signaling pathway(s) and 
responses in cancer cells even when administered at low 
concentrations comparable to those of metformin [16]. 
HL156A is capable of inducing AMPK signaling [17]. 
HL156A has been reported to exert protective effects 
against peritoneal and liver fibrosis- and 
lipopolysaccharide (LPS)-induced inflammation [17, 
18]. In addition, HL156A inhibits not only high 
glucose-activated smad3-dependent signaling but also 
epithelial-mesenchymal transition (EMT) [18]. A recent 
study showed that HL156A, when administered in 
combination with temozolomide, inhibited the invasive 
properties of glioblastoma and increased the survival 
rate in an animal model [19]. We also observed that 
HL156A is associated with a decreased risk of 
developing oral cancers, especially squamous 
carcinoma cell cancers. Although metformin may have 
Figure 1. Macroscopic phenotype of SAMP1/kl-deficient mice. (A) Gross appearance of deficient (SAMP1/kl-/-) mice at 4 weeks 
of age. (B) Body weight curves for 4- to 11-week-old Klotho-deficient (kl-/-) and compound-deficient (SAMP1/kl-/-) mice. (C) Survival 
curves for the groups of SAMP1/kl+/+ (n=6) and SAMP1/kl-/- (n=7) mice. 
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effects similar to those of HL156A, the delivery of 
metformin to the tissue is limited because its 
hydrophilic nature prevents it from entering cells. 
HL156A overcomes this shortcoming and shows 
generally high bioavailability. The present study was 
designed to examine the effect of HL156A on metabolic 
changes that induce against aging-dependent oxidative 
stress in the kidneys of SAMP1/kl-/- mice, which 
represent a mouse model of accelerated aging. 
RESULTS 
SAMP1/kl-deficient mice characteristics 
Heterozygous kl+/- mice were mated with SAMP1 mice 
to characterize the aging phenotype in this hybrid 
background. Like kl-/- mice, the SAMP1/kl-/- began to 
exhibit growth retardation, inactivity and multiple 
features resembling those associated with premature 
aging. Survival age was recorded as the age at which 
the mice either died or were euthanized because of 
problems with their health. The mean survival age of 
the SAMP1/kl-/- mice was 9.3 weeks old (n = 7), 
whereas that of the klotho-/- mice was 12 weeks old 
(n = 5). In gross appearance, the SAMP1/kl-/- mice 
were smaller in size, exhibited skin atrophy, and 
developed alopecia (Fig. 1A). Body weight was lower 
in the SAMP1/kl-/- mice than in the klotho-/- mice 
beginning at 1 month of age (Fig. 1B). Microscopic 
examination showed that more extensive inflammation 
and calcification was observed in the tissues of the 
SAMP1/kl-/- mice than in those of the klotho-/- mice 
(Table S1) 
Modulation of IGF-1/Akt/mTOR, FOXO1, and 
MAPK signaling proteins by HL156A 
We isolated MEFs from SAMP1/kl+/+ and SAMP1/kl-
/- mouse embryos obtained at embryonic day 13 (E13). 
We ﬁrst investigated the effects of SAMP1/kl 
deficiency on cell proliferation. At 24 and 48 h, 
proliferation was slower in the SAMP1/kl-/- MEFs than 
in the SAMP1/kl+/+ MEFs (Fig. 2A). 
One of the mechanisms that exhibits gradual changes in 
activity during aging is the IGF-1/ Forkhead 
transcription factor (FOXO1) axis. To examine the 
signaling mechanisms that might regulate cell growth in 
SAMP1/kl-/- MEFs, we focused our attention on the 
IGF-1/FOXO1 pathway. RT-PCR and Western blot 
analyses showed that the mRNA and protein expression 
levels, respectively, of IGF-1 were more than 5-fold 
higher in the SAMP1/kl-/- MEFs. FOXO1 was 
expressed at lower levels in SAMP1/kl-/- MEFs, than in 
SAMP1/kl+/+ cells. There was no difference in the 
mRNA expression of FOXO3 between SAMP1/kl+/+ 
and SAMP1/kl-/- MEFs (Fig. 2B and C). In addition, 
we observed that FOXO1 is induced by soluble klotho 
overexpression and recombinant soluble klotho proteins 
(Fig. S1). To determine whether the new metformin 
derivative, HL156A, affects the IGF-1/FOXO1 axis, we 
used real-time PCR and Western blot analyses to 
quantify the mRNA and protein levels, respectively, of 
FOXO1. As shown in Figure 2D-2F, IGF-1 levels were 
decreased by HL156A (10 or 20 μM) in both 
SAMP1/kl+/+ and SAMP1/kl-/- MEFs. Additionally, 
HL156A increased the mRNA and protein expression 
levels of FOXO1 in a concentration-dependent manner. 
The IGF-I/AKT/mTOR signaling pathway plays 
important roles in regulating cell growth, proliferation, 
differentiation, motility, survival, and longevity. 
Therefore, we next examined whether HL156A 
regulates the expression of IGF-1/AKT/mTOR 
signaling proteins in SAMP1/kl+/+ and SAMP1/kl-/- 
MEFs. In SAMP1/kl+/+ and SAMP1/kl-/- MEFs, 
treatment with HL156A inhibited the phosphorylation 
of AKT, mTOR, and p70S6K in a concentration- or 
time-dependent manner (Fig. 2G). Consistent with these 
results, in SAMP1/kl-/- MEFs, the phosphorylation of 
GSK3b was also reduced after 24 or 48 h of incubation 
in the presence of HL156A (Fig. 2H). Previous studies 
have established that there is a relationship between 
IGF-I, mitogen-activated protein kinase (MAPK)/ERK 
and p53 [20]. Western blot results (Fig. 2I) 
demonstrated that phosphorylation of MAPKs was 
inhibited in HL156A-treated SAMP1/kl-/- MEFs, while 
total MAPK levels remained unaltered. In addition, 
when cells were treated with HL156A, the protein 
expression levels of P53 and p21 also decreased in a 
time-dependent manner (Fig. 2I). These results showed 
that HL156A inhibits the Akt/mTOR and MAPKs 
signal transduction pathways. 
HL156A increases mitochondrial membrane 
potential and inhibits ROS formation  
To further explore the link between ROS formation and 
klotho depletion, intracellular ROS production was 
assessed with fluorescence microscopy using the 
oxidation-sensitive dye DHE. Our results demonstrate 
that ROS levels were substantially higher in SAMP1/kl-
/- MEFs than in SAMP1/kl+/+ MEFs, suggesting that 
ROS play a significant role in the senescence observed 
in SAMP1/kl-/- MEFs. Treatment of HL156A 
significantly reduced the number of DHE-positive 
SAMP1/kl-/- MEFs (Fig. 3A and 3B). In addition, we 
found that the mitochondria of SAMP1/kl-/- MEFs 
exhibited a more oxidizing state than was observed in 
SAMP1/kl+/+ MEFs (data not shown).   
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Figure 2. Effect of HL156A on IGF-I-mediated FoxO1 signaling in SAMP1/kl-/- MEFs. (A) Effect of SAMP1/kl-/- depletion on 
cell proliferation. SAMP1/kl+/+ and SAMP1/kl-/- MEFs were plated in 48-well plates at a density of 5 x 104 cells/well, and cell 
proliferation was evaluated using MTT assays after 24 and 48 h. (B) Comparison of IGF-1, FOXO1, and FOXO3 expression in 
SAMP1/kl+/+ and SAMP1/kl-/- MEFs. Total RNA was extracted from SAMP1/kl+/+ and SAMP1/kl-/- MEFs. cDNA was synthesized by 
reverse transcription-polymerase chain reaction (RT-PCR). (C) The mRNA levels of IFGR and FOXO1 were determined in SAMP1/kl+/+ 
and SAMP1/kl-/- MEFs. Total protein was extracted, and the protein levels of IFGR, p-IGFR, and FOXO1 were measured by Western blot. 
Actin was used as a loading control. (D) The effect of HL156A on IGF-1 signaling. SAMP1/kl+/+ and SAMP1/kl-/- MEFs were incubated in 
the absence or presence of HL156A (10 or 20 μM) for 24 h, and total RNA was then isolated and subjected to RT-PCR analysis to 
determine the mRNA levels of IGF-I, FOXO1, and mTOR. (E) Changes in the mRNA abundance of FOXO1 were analyzed with real-time 
RT-PCR analysis in HL156A-treated SAMP1/kl+/+ and SAMP1/kl-/- MEFs. (F) HL156A induced FOXO1 expression. Cells were treated with 
HL156A for 24 h, and FOXO1 levels were then determined using Western blot analysis. (G) The effect of HL156A on IGF-I-mediated 
Akt/mTOR/p70S6K signaling. The expression of IGF-I-mediated Akt/mTOR/p70S6K proteins in SAMP1/kl+/+ and SAMP1/kl-/- MEFs 
treated with HL156A (10 or 20 μM) for 24 h. (H) Immunoblotting analysis of GSK3β, Akt, mTOR, and p70S6K expression in SAMP1/kl-/- 
MEFs treated for 24 or 48 h with 20 μM HL156A. (I) Effects of HL156A on MAPK activation in SAMP1/kl-/- MEFs. 
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It has been reported that mitochondrial malfunction 
leads to the accumulation of ROS [21]. To determine 
whether HL156A induced changes in the mitochondrial 
membrane potential, the mitochondrial membrane 
potential activity of cells was assessed with JC-1. JC-1 
is a fluorescent cationic dye that can selectively enter 
mitochondria. It reversibly changes color from red to 
green as membrane potential decreases. Interestingly, 
red fluorescence was increased in the HL156A-treated 
SAMP1/kl-/- MEFs, suggesting that HL156A increased 
membrane potential by inhibiting ROS (Fig. 3C). The 
next step was to confirm our hypothesis that HL156A 
inhibits cell senescence by increasing the mitochondrial 
membrane potential in SAMP1/kl-/- MEFs. We 
examined SA-β-gal activity in SAMP1/kl-/- MEFs 
treated with HL156A. As shown in Figure 3D, 
treatment with HL156A reduced the number of SA-β-
gal-positive SAMP1/kl-/- MEFs. 
CE-TOFMS was used to evaluate the metabolic 
profiles of SAMP1/kl-/- mouse kidneys treated with 
HL156A 
Following on the previous finding that HL156A exerts 
an antioxidative effect in vitro, SAMP1/kl-/- mice were 
used to examine HL156A-induced alterations in in vivo 
pathological characteristics. SAMP1/kl-/- mice were 
randomized into an untreated group (controls) and a 
group that was orally administered HL156A (30 mg/kg) 
throughout the duration of the experiment. The body 
weights of the mice were checked every other day. As 
shown in Fig. 4A, a survival analysis performed with 
Figure 3. Effects of HL156A on ROS production, mitochondrial membrane potential, and aging in SAMP1/kl-deficient 
MEFs. (A, B) ROS production in SAMP1/kl+/+ and SAMP1/kl-/- MEFs. ROS levels were measured in SAMP1/kl+/+ and SAMP1/kl-/- MEFs 
treated with/without HL156A (20 or 30 μM). Cells were viewed using fluorescence microscopy. The graph was derived from 3 
independent experiments. (C) Effect of HL156A on mitochondrial membrane potential activity in SAMP1/kl-/- MEFs. Cells were 
incubated with 20 μM HL156A for 24 h, and the level of the fluorogenic probe JC-1 was then determined to analyze mitochondrial 
membrane potential. (D) Effect of HL156A on aging in SAMP1/kl-/- MEFs. SAMP1/kl-/- MEFs were exposed to 20 μM HL156A for 24 h. 
Cell senescence was analyzed with senescence-associated β-galactosidase (SA-β-gal) staining. 
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Kaplan-Meier survival curves of the SAMP1/kl-/- mice 
revealed that there was a significant difference in 
survival, which was significantly lower in the untreated 
controls (n=7, 49 days) than in the HL156A-treated 
(n=6, 80 days) mice. 
A metabolome analysis was performed in 3 samples of 
mouse kidney tissue (SAMP1/kl+/+, SAMP1/kl-/-, and 
HL156A-treated SAMP1/kl-/-) using CE-TOFMS in 
two modes for cationic and anionic metabolites. We 
detected 232 metabolites (149 metabolites in cation 
mode and 83 metabolites in anion mode) on the basis of 
the HMT’s standard library. The results for the 232 
detected peaks are summarized in Supplementary Table 
2 (Table S2).  
These metabolites were found to be associated with 
glycolysis/gluconeogenesis, the pentose-phosphate 
pathway, the tricarboxylic acid cycle, the urea cycle, 
pyrimidine metabolism, glutathione metabolism, 
nicotinate and nicotinamide metabolism and amino acid 
metabolism. The results of our comparison of the 
metabolic profiles of these tissues are shown in Figure 
5B. A PCA analysis revealed that there was a very clear 
distinction between the abundance of intracellular 
metabolites in the SAMP1/kl+/+ and SAMP1/kl-/- 
tissues that were or were not treated with HL156A. The 
first component (PC1) indicated that 70.7% of the total 
variance was due to the difference between the 
SAMP1/kl+/+ and SAMP1/kl-/- samples and the 
HL156A-treated SAMP1/kl-/- sample. The PC2 
component indicated that 29.4% of the variance was 
due to the difference between the HL156A-treated 
SAMP1/kl-/- and SAMP1/kl-/- kidney tissue samples 
(data not shown). Furthermore, a heat-map analysis 
indicated that the metabolic pattern of the SAMP1/kl-/- 
kidney sample was almost completely opposite that of 
the SAMP1/kl+/+ kidney sample. We also observed that 
there was a clear difference between the HL156A-
treated SAMP1/kl-/- kidney sample and the SAMP1/kl-
/- kidney sample (Fig. 4B). The metabolic pathways 
associated    with    all    the   detected   metabolites   are  
Figure 4. A comparison of the metabolic profile of mouse kidney tissues (SAMP1/kl+/+, SAMP1/kl-/-, and HL156A-
treated SAMP1/kl-/-) was performed by CE-TOFMS. (A) Survival curves for the SAMP1/kl-/- and Hl156A-treated SAMP1/kl-/- 
mice. (B) The horizontal axis and vertical axis show the sample names and peaks, respectively. HCA was performed for the peaks. The 
distances between peaks are displayed in tree diagrams.  
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illustrated in Supplementary Figure 2 (Fig. S2). 
HL156A inhibits the production of oxidized 
glutathione (GSSG) in SAMP1/kl-/- kidneys 
We first compared the relative amounts of glutathione 
metabolites between SAMP1/kl+/+, SAMP1/kl-/-, and 
HL156A-treated SAMP1/kl-/- mouse kidney tissues 
because we previous showed that HL156A inhibited the 
increase of ROS in SAMP1/kl-/- MEFs. 
When the results for the glutathione biosynthesis 
pathways were plotted (Fig. 5A and 5B), we found that 
the level of the reduced form of glutathione, GSH, was 
dramatically lower in the SAMP1/kl-/- mouse kidney 
tissues. These changes in metabolites are likely linked 
to the oxidation of glutathione, causing GSH depletion, 
and the associated depletion of glutathione biosynthesis 
intermediates. However, the level of cysteinylglycine, 
an essential amino acid dipeptide located upstream of 
cysteine in the glutathione synthesis pathway, was 2.0-
fold higher in the HL156A-treated kidneys than in the 
SAMP1/kl-/- kidneys. We also found that in the 
HL156A-treated SAMP1/kl-/- kidneys, cysteine was 
reunited with glutamate to form γ-glutamylcysteine, a 
precursor dipeptide of GSH biosynthesis (Fig. S3).  
Notably, GSH levels were 2.7-fold higher in the 
HL156A-treated SAMP1/kl-/- kidney than in the 
SAMP1/kl-/- kidney. In contrast, the level of oxidized 
glutathione (GSSH) was lower (0.8-fold) in the 
HL156A in SAMP1/kl-/- kidney than in the SAMP1/kl-
/- kidney (Fig. S3). 
As indicated in Figure 3, HL156A mitigated oxidative 
damage in kidney tissues by down-regulating ROS 
production. To confirm the link between glutathione 
production and the in vivo antioxidative effects of 
HL156A, the GSH/GSSG ratio was measured in 
SAMP1/kl+/+, SAMP1/kl-/-, and HL156A-treated 
SAMP1/kl-/- kidney tissues. 
The results showed that the GSH/GSSG ratio was lower 
in the samples obtained from SAMP1/kl-/- kidney 
tissues than in those obtained from control mice that 
were 4 and/or 8 weeks old (Fig. 5C). However, 
administration of 30 mg/kg of HL156A increased GSH 
levels and restored antioxidant capacity, as illustrated 
by an increased GSH/GSSG ratio (Fig. 5D). We also 
observed that HL156A induced the reduced form GSH 
reduced by H2O2-mediated oxidative stress in MEF kl-/- 
cells (Fig. 5E). These consequences suggest that 
HL156A supplementation protected the kidneys against 
oxidative stress. 
Effects of HL156A on pathological changes in the 
kidneys of SAMP1/kl-/- Mice 
As previously described, oxidative stress injury 
participates in the mechanisms underlying acute kidney 
injury [22]. To confirm whether the HL156A-induced 
increase in GSH is related to the evolution of 
SAMP1/klotho deficiency-induced kidney injury, 
histological sections of kidney tissues were stained with 
hematoxylin-eosin, GSH and a FOXO1 antibody and 
subjected to von Kossa staining. SAMP1/kl-/- mice (4 
weeks old) were randomized to an untreated control 
group or orally administered HL156A (30 mg/kg) or N-
acetyl-L-cysteine (NAC, 100 mg/kg), and ROS 
scavenger, for 1 month. Histological analysis of these 
animals revealed that they exhibited severe phenotypes 
comparable to those observed in SAMP1/kl+/+ mice. 
As mentioned above, we detected atrophy of the 
kidneys as well as glomerular atrophy in the SAMP1/kl-
/- mice. However, the number of GSH- and FOXO1-
positive cells was significantly increased in HL156A-
treated kidney sections compared with kidneys from 
control SAMP1/kl-/- mice (Fig. 6A and 6B). Von-Kossa 
staining showed that in comparison to the wild type 
mice, the SAMP1/kl-/- mice exhibited excessive 
vascular and tubular calcification in the kidneys (Fig. 
6C). In contrast, the SAMP1/kl-/- mice were 
continuously treated with HL156A for 4 weeks 
exhibited attenuated calcification in the kidneys.  
Treatment with the antioxidant NAC also decreased the 
accumulation of calcification in SAMP1/kl-/- mice. The 
same results were observed when we examined tongue 
tissues obtained from HL156A-treated mice (Fig. S4). 
DISCUSSION 
Klotho-deficient mice showed numerous phenotypes 
consistent with premature aging, including kyphosis, 
slow movement, infertility, severe skeletal muscle 
reduction, and osteopenia, as well as atrophy of the 
skin, intestines, thymus, spleen and kidneys [2, 3]. 
Klotho (-/-) mouse models have previously been used to 
study aging-related disease [23, 24 25], and these 
models have shown that in these mice, phosphate and 
Ca2+ channel pathways (the sodium-phosphate 
cotransporters NaPi2a and TRPV5) are genetically 
altered, factors involved in the inflammation response 
(NF-κB, IL-6 and IL-8) are modulated, and oxidative 
stress signaling (ROS) is induced [26, 27, 28]. These 
studies can be useful for investigating specific aspects 
of klotho depletion-induced disease pathogenesis, but 
their results do not reflect the complexity of the human 
aging process,  which  is  increased  by  the  presence of  
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Figure 5. HL156A-mediated changes in intermediates of glutathione metabolism. (A) The levels of intermediates of 
glutathione metabolism were plotted on pathway maps. The relative quantities of the detected metabolites are represented as bar 
graphs (from left to right: SAMP1/kl+/+ (blue), SAMP1/kl-/- (red), and HL156A-treated SAMP1/kl-/- (green) kidneys). (B) Comparisons of 
the relative amounts of glutathione metabolites between SAMP1/kl+/+, SAMP1/kl-/-, and HL156A-treated SAMP1/kl-/- mouse kidneys. 
(C) In vivo effect of HL156A administration on glutathione status in SAMP1/kl-/- mice. Oxidized (GSSG)/reduced (GSH) ratios in mouse 
kidneys and livers obtained from SAMP1/kl+/+ or SAMP1/kl-/- mice. (D) GSSG/GSH ratios in mouse kidneys obtained from mice orally
administered 0.9% saline solution (control) or 30 mg/kg HL156A every other day for 12 weeks. GSH and GSSG levels were quantified by
spectrophotometry, and GSSG/GSH ratios were calculated as estimates of oxidative stress. (E) In vitro effect of HL156A on GSSG/GSH
ratios in H2O2-treated MEF kl-/- cells. H2O2-treated cells were co-incubated with 20 or 40 μM HL156A for 36 h. *p<0.05. **p<0.001.
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other anti-aging genetic backgrounds and factors in the 
immune system. 
The Senescence-Accelerated Mouse (SAM) was 
developed as another model for studying human aging 
and age-related diseases. Senescence-prone 1 (SAMP1) 
strains exhibit the early onset of age-related disease 
symptoms, such as senile amyloidosis, contracted 
kidneys, an impaired immune response, the 
hyperinflation of the lungs, hearing impairment, and 
hypertensive vascular disease [29]. To more 
comprehensively explore the complexity of human 
aging, we created SAMP1/kl-deficient (SAMP1/kl-/-) 
mice. Matings between SAMP1/kl hetero animals 
(SAMP1/kl+/-) had a one-in-four chance to produce 
compound homozygous mice (SAMP1/kl-/-). As 
expected, SAMP1/kl-/- mice exhibited an aging 
phenotype that was nearly identical to that of Klotho-
deficient (kl-/-) mice. The SAMP1/kl-/- mice displayed 
atrophy of the skin, intestines, thymus, spleen and 
kidneys in a manner very similar to that observed in the 
klotho null phenotype. One of the major complications 
observed in SAMP1/kl-/- mice was a large amount of 
ectopic calcification and inflammation in some tissues, 
including the salivary glands, thymus, lungs, kidneys, 
and stomach. Furthermore, mechanistic studies showed 
Figure 6. Histological features of the kidneys of HL156A-treated SAMP1/kl-/- mice. (A, B) Changes in glutathione and FOXO1 
levels in the kidneys of HL156A-treated SAMP1/kl-/- mice (original magnification x40 or x200). (C) Representative sections were labeled 
with von Kossa stain. Photomicrographs of kidneys of SAMP1/kl-/- and HL156A- or nicotinamide (NAC)-treated SAMP1/kl-/- mice. 
Kidney tissue sections were evaluated using von Kossa staining to identify calcium deposits.  
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that the high level of IGF-1 expression induced in 
SAMP1/kl-deficient MEFs inhibited the expression of 
FOXO1, which is regulated by IGF-1 signaling. These 
data suggest that SAMP1/kl-deficient cells or tissues 
cannot participate in the removal of ROS and, therefore, 
cannot protect against oxidative stress. We 
demonstrated that the level of ROS was substantially 
higher in SAMP1/kl-/- MEFs than in SAMP1/kl+/+ 
MEFs, suggesting that ROS play a significant role in the 
senescence observed in SAMP1/kl-/- MEFs. We further 
used SA-β-gal assays to confirm our hypothesis that the 
level of cell senescence was higher in SAMP1/kl-/- 
MEFs than in SAMP1/kl+/+ MEFs.  
As mentioned above, cell growth rates were 
significantly slower in the SAMP1/kl-/- MEFs (≥60% at 
24 h) than in SAMP1/kl+/+ MEFs, while the mRNA 
level of IGF-1 was higher in SAMP1/kl-/- MEFs. In 
addition, IGF-1R protein phosphorylation was also 
increased in SAMP1/kl-/- MEFs. These data indicate 
that SAMP1/klotho depletion plays a direct role in the 
induction of IGF-1/IGFR signaling. Activated IGF-
1/IGFR signaling may inhibit FOXO1 expression, a key 
regulator of antioxidant signaling, in SAMP1/kl-/- 
MEFs. Because FOXO1 plays important roles in stress 
resistance and metabolic function, inhibiting IGF-
1/IGF-1R signaling may represent a potential approach 
for treating oxidative stress induced aging.  
There is growing interest and demand for research that 
addresses the aging process. During 60 years of the use 
of metformin in type 2 diabetes, researchers found that 
metformin has additional anti-aging effects as well as 
effects on glycaemic control. Although, metformin’s 
effect on clinical aging outcomes is still considered a 
theoretical approach, the findings from studies in 
cellular and animal models have shown the beneficial 
effects on aging. Here, we present a new mouse model 
of the aging process and the mechanisms involved and 
describe the role that the metformin derivative HL156A 
may have in inhibiting these mechanisms. Although 
metformin may have effects similar to those of 
HL156A, the delivery of metformin to the tissue is 
limited. Metformin presents limitations as an antiaging 
or anticancer drug because its hydrophilic nature 
prevents it from entering cells [30]. However, HL156A 
overcomes this shortcoming and shows generally high 
bioavailability.  
The results of the present study show that HL156A 
exerts an antioxidative effect by inhibiting 
IGF/AKT/mTOR signaling and inducing FOXO1 
expression. Specifically, we found that HL156A 
inhibited AKT phosphorylation/activation and repressed 
the phosphorylation of mTOR and p70S6K in 
SAMP1/kl MEFs regardless of whether the cells 
expressed klotho. HL156A also inhibits MAPK 
pathways that are important for cellular signaling, 
including pathways involved in the cell cycle, cell 
proliferation, cell differentiation, and cell death, 
suggesting that MAPKs also play key roles in HL156A-
mediated processes.  
Here, we investigated whether HL156A regulates 
oxidative stress in SAMP1/kl-/- MEFs. Our results 
show that HL156A decreased intracellular ROS levels 
and increased membrane potential in SAMP1/kl-/- 
MEFs. Previous studies showed that the beneficial 
effect of metformin and metformin derivatives on 
mitochondrial oxidative stress were mediated by a 
reduction in ROS production [31, 32] or the activation 
of AMPK/FOXO and mitochondrial biogenesis [33]. 
Our data may explain, in part, the beneficial effects on 
mitochondrial membrane potential that were have 
observed in SAMP1/kl-/- MEFs treated with HL156A, 
and these results suggest that HL156A-stimulated cells 
may have a unique metabolic profile with regard for the 
antioxidant system. 
Next, we used CE-TOFMS to explore the effects of 
HL156A on the metabolomic profile of SAMP1/kl+/+ 
and SAMP1/kl-/- mouse kidneys. The results revealed 
that the levels of various metabolites obviously differed 
between SAMP1/kl+/+ and SAMP1/kl-/- mice. Our 
analysis specifically revealed that the levels of 
metabolites associated with the central carbon, amino 
acid, and coenzyme pathways and trimethylaminuria 
metabolism, glutathione metabolism, the pentose-
phosphate pathway, and nicotinate/nicotinamide 
metabolism differed between and SAMP1/kl-/- and 
HL156A-treated SAMP1/kl-/- mice. Interestingly, the 
levels of metabolites of antioxidants, such as carnosine, 
ergothioneine, and glutathione (GSH), were increased in 
HL156A-treated SAMP1/kl-/- kidneys. Conversely, the 
level of oxidized glutathione (GSSG) was decreased 
under these conditions. These findings suggest that 
HL156A blocked oxidative stress in SAMP1/kl-/- mice 
and consequently inhibited ROS production. 
Additionally, we confirmed that HL156A influences 
GSH redox balance in vivo. The GSH/GSSG ratio was 
increased in kidney and/or liver tissues obtained from 
HL156A-treated SAMP1/kl-/- mice at 4 or 8 weeks of 
age. Furthermore, the level of cysteinylglycine, an 
essential amino acid dipeptide located upstream in the 
cysteine synthesis pathway, was 2-fold higher in 
HL156A-treated mouse kidneys than in the SAMP1/kl-
/- kidney. We also found that the cysteine was reunited 
with glutamate and formed γ-glutamylcysteine, a 
precursor dipeptide of GSH biosynthesis. In addition, 
we observed that HL156A inhibited citric acid and 
stachydrine metabolites known to be involved in kidney 
disease (data not shown). The results of this study show 
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that HL156A induces a reduced form glutathione to 
modulate mitochondrial and non-mitochondrial 
oxidative stress and ameliorate renal injury caused by 
the accumulation of Ca2+.  
In our CE-TOFMS analysis, we also found that the 
increased levels of myo-inositol 1-phosphate and myo-
inositol 3-phosphate observed in SAMP1/kl-/- kidneys 
were inhibited by treatment with HL156A. In 
mammalian cells, myo-inositol and its derivatives, such 
as phosphoinositides (PIs) and inositol phosphates, are 
involved in various biochemical and physiological 
processes, including reproduction [34], embryonic 
development [35, 36], and neuronal functions [37, 38]. 
The dysregulation of inositol homeostasis has been 
reported to be a factor in neurodegenerative diseases, 
including Alzheimer’s disease [39], Huntington’s 
disease, and Parkinson’s disease [40]. Accordingly, 
HL156A, which targets inositol phosphate metabolism 
activities responsible for slowing down aging and 
postponing the onset of age-related diseases, including 
neurodegenerative diseases, may be an important target 
for therapeutic interventions with high clinical 
relevance. 
Similar to klotho-/- mice, SAMP1/kl-/- mice develop 
aging-related disease without chemical or immunologic 
manipulation and exhibit a remarkably similarity to the 
human aging phenotype. Additionally, in these mice, 
disease severity deteriorates over time. The present 
study was conducted to quantify the effects of HL156A 
treatment on the progression of kidney pathology in 
SAMP1/kl-/- mice, which exhibit a phenotype that 
reflects the complexity of human aging. We observed 
that the survival rate was higher in SAMP1/kl-/- mice 
treated with HL156A than in SAMP1/kl-/- mice. In 
particular, HL156A-treated SAMP1/kl-/- mice showed a 
significant increase in reduced glutathione (GSH) as 
well as a decrease in oxidized glutathione (GSSG). 
Histological analyses showed that HL156A treatment 
decreased calcification in SAMP1/kl-/- mice, while 
SAMP1/kl-/- mice generally displayed high-grade 
calcification. These results collectively indicate that 
SAMP1/kl-/- mice may represent a relevant model for 
investigating the pathogenic mechanisms underlying 
aging and that HL156A is a potential preclinical 
therapeutic modality for treating renal disease, 
including acute kidney disease (AKD) and early chronic 
kidney disease (CKD). 
MATERIALS AND METHODS 
Generation of SAMP1/kl deficient mice 
Senescence-Accelerated mice (SAMP1, 7 weeks old) 
were purchased from Japan SLC, Inc. (Hamamatsu, 
Japan). SAM mice are a group of inbred mouse strains 
(AKR/J mice) that are used as models to study human 
aging and age-related diseases [29]. Heterozygous 
klotho mice (kl+/-) were generously provided by Dr. 
Kuro-O (University of Texas Southwestern, Dallas, TX, 
USA). The klotho-/- mice were generated as previously 
described [2]. To generate a line of SAMP1/Klotho-
deficient mice (SAMP1/kl-/-), we crossed SAMP1 and 
Klotho heterozygous mice (kl+/-). SAMP1/kl+/+ and 
SAMP1/kl-/- mice were then derived from 
SAMP1/kl+/- heterozygous breeding pairs. Tail biopsies 
were performed for genotyping. DNA was extracted and 
tested for the presence of wild type and mutant alleles.  
Derivation of mouse embryonic fibroblasts from 
klotho-deficient mice 
Mouse embryonic fibroblasts (MEFs) were derived and 
cultured from SAMP1/kl+/+ and SAMP1/kl-/- 13-day-
old embryos that were obtained by mating SAMP1/kl+/- 
mice with SAMP1/kl+/- mice according to a previously 
reported protocol. MEFs were cultured in 10 cm2 cell 
culture flasks in DMEM (Gibco/Life Technologies, 
Grand Island, NY) containing 10% fetal bovine serum 
(FBS), 100 units/ml penicillin, and 100 µg/ml 
streptomycin (Invitrogen, CA) at 37°C in 5% CO2 for 3 
passages. Then, the cells were harvested and frozen in 
the same medium but with 5% DMSO and no 
antibiotics.  
Cell proliferation assay 
Cell proliferation was assessed using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma-Aldrich, St. Louis, MO) assays. The cells 
were seeded in 96-well plates at a density of 2 × 103 
cells/well. Absorbance was measured at 540 nm using a 
DTX 880 Multimode Detector (Beckman Coulter, Brea 
CA, USA). HL156A is a derivative of phenyl 
biguanide, which is designed and synthesized by Hanall 
Biopharma Inc. (Seoul, Korea). The detailed procedure 
for HL156A synthesis and the structure of HL156A 
were described in a previous study [18,19].  
RNA purification and RT-PCR 
Total RNA was isolated from MEFs obtained from wild 
type or klotho-/- mice using TRIzol reagent (Invitrogen, 
USA). To avoid genomic DNA contamination, the 
extracted RNA was purified using an RNeasy kit 
(Invitrogen, USA). The sequences of the RT-PCR 
primers were as follows: IGF-1: forward 5'-
TACAAAAGCAGCCCGCTCTA-3' and reverse 5'-
GGTGATGTGGCATTTTCTGC-3', FOXO1: forward 
5'-TTGTCATAGGCTTCCCACCA-3' and reverse 5'-
AGACCCGGGTTCTTTGACAC-3', FOXO3: forward 
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5'-GAACTCATGGATGCTGACGG-3' and reverse 5'-
AGCAGATTTGGCAAAGGGTT-3', mTOR: forward 
5'-GAACCTGGCTCAAGTACGCA-3' and reverse 5'-
GCTTATGCAGCTCCTGCTTG-3', and GAPDH: 
forward 5'-CCAAGGTCATCCATGACAACT-3' and 
reverse 5'-GTCATACCAGGAAATGAGCTTG-3'. The 
PCR products were then electrophoresed on a 2% 
acrylamide gel and visualized using a gel 
documentation system (Bio-Rad, Hercules, CA, USA). 
Western blot analysis 
Total protein was obtained from the cells using RIPA 
buffer (50mM Tris-Cl [pH 7.5], 150 mM NaCl, 0.5% 
sodium deoxycholate, 1% NP-40, 0,1% SDS and 1 mM 
EDTA) containing a protease inhibitor cocktail (1 μg/ml 
aprotinin and leupeptin). Cell lysates (30 μg) were 
subjected to SDS–PAGE and then transferred to 
nitrocellulose membranes (Amersham Pharmacia 
Biotech, UK). The membranes were blocked in 5% 
skim milk for 3 h and then incubated with primary 
antibodies against p70S6K (sc230), p-p70S6K (sc8416), 
p-mTOR (sc 101738), p53 (sc126), p21 (sc6246), GSK-
3β (sc9166), β-actin (sc47778) purchased from Santa
Cruz (Texas, USA); mTOR (2972S), IGFR-1 (3027S),
pIGFR-1 (3024S), AKT (9272S), pAKT (4060S),
Erk1/2 (9102S), p-Erk1/2(9101S), p-GSK-3α/β
(8566S), p38 (9212S), p-p38 (9211S), p-JNK (9251S),
JNK (9252S), and FoxO1 (2880S) purchased from Cell
Signaling (Massachusetts, USA) for 4 h at room
temperature (RT) (dilution ratio 1:1000). After being
washed twice, the membranes were incubated with the
corresponding secondary antibodies for 1 h (dilution
ratio 1:5000). Protein signals were detected with a
Luminescent image analyzer (Las-1000; Fujifilm,
Japan).
ROS formation detection 
Reactive oxygen species (ROS) levels were determined 
based on the oxidation of dihydroethidium (DHE). Cells 
were seeded and grown to 70-80% confluency. They 
were then incubated with HL156A for 24 h. The cells 
were subsequently treated with DHE (10 mM) for 30 
min at 37°C in the dark. DHE fluorescence was detected 
with a fluorescence microscope (IX-71; Olympus, 
Tokyo, Japan) and multimode ELISA reader (Beckman 
Coulter Inc., Wals, Austria). 
Mitochondrial membrane potential 
Mitochondrial membrane potential was analyzed with a 
fluorescence microscope (IX-71; Olympus, Tokyo, 
Japan) using a JC-1 mitochondrial membrane potential 
detection kit. JC-1 accumulates in a potential-dependent 
manner in mitochondria and is indicated by a 
fluorescence emission shift from green (530 nm, FL-1 
channel) to red (590 nm, FL-2 channel).  
Metabolome profiles of mouse kidney tissue by CE-
TOFMS analysis 
Metabolome analyses were performed for 3 samples of 
mouse kidney tissue (SAMP1/kl wild type, SAMP1/kl-
/-, and HL156A-treated klotho-/-) using Capillary 
Electrophoresis Time-of-Flight Mass Spectrometry 
(CE-TOFMS) in two modes for cationic and anionic 
metabolites. The samples were mixed with 50% 
acetonitrile in water (v/v) containing internal standards 
(20 μM for cation and 5 μM for anion measurement) 
and homogenized by a homogenizer (1,500 rpm, 120 
sec × 4 times). The supernatant (400 μL × 2) was then 
filtrated through a 5-kDa cut-off filter (ULTRAFREE-
MC-PLHCC, Human Metabolome Technologies, 
Yamagata, Japan) to remove macromolecules.  
Data Processing and Analysis 
Peaks detected in the CE-TOFMS analysis were 
extracted using automatic integration software 
(MasterHands ver. 2.16.0.15 developed at Keio 
University) and used to obtain peak information, 
including m/z, migration time (MT), and relative peak 
area (peak area = metabolite peak area / (internal 
standard peak area × sample amount). The following 
statistical analyses were performed: hierarchical cluster 
analysis (HCA) in PeakStat ver. 3.18 (in-house 
software) and principal component analysis (PCA) in 
SampleStat ver. 3.14 (in-house software). The profiles 
of peaks associated with putative metabolites were 
represented on metabolic pathway maps using 
Visualization and Analysis of Networks containing 
Experimental Data (VANTED) 4 software. The 
abbreviations used for some metabolites shown in the 
pathway map are different from those used in the 
Human Metabolome Technologies (HMT) standard 
library. The pathway map was prepared based on 
metabolic pathways known, according to the KEGG 
database (http://www.genome.jp/kegg/) to exist in 
human cells. 
GSH/GSSG measurement 
Glutathione measurements were performed as 
previously described [41]. Kidneys obtained from 
SAMP1/kl-/- mice were homogenized in 5% 
sulfosalicylic acid buffer (1:3, w/v) at 4°C and 
centrifuged at 12,000×g. The resulting supernatants 
were transferred to Eppendorf tubes and kept on dry ice 
until assayed for glutathione content. Standards and 
tissue homogenates were assayed in triplicate. 
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Reactions were started by combining the sample with 
glutathione reductase.  
Tissue preparation and histological examination 
All animals were anesthetized and killed, and their 
kidneys were then dissected. The kidney tissues were 
fixed in 10% formalin, embedded in paraffin and cut 
into 4 µm-thick sections for staining. All sections were 
stained with hematoxylin and eosin and anti-GSH or 
anti-FOXO1. Sections of kidneys were also processed 
for von Kossa staining to detect histological alterations, 
such as calcification.  
Statistical analysis 
Statistical analysis was performed with the data 
obtained from three independent experiments. The data 
are presented as the mean ± s.e.m. A p-value <0.05 was 
considered significant. 
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SUPPLEMENTARY MATERIAL 
Please browse the links in Full Text version of this manuscript to see Supplementary Tables. 
Supplementary Table S1. Histological changes in the tissues of SAMP1/kl deficient mice. 
Supplementary Table S2. Changes in putative metabolites in the kidneys of SAMP1/kl+/+, SAMP1/kl-/-, and 
HL156A-treated SAMP1/kl-/- mice. 
Supplementary Figure S1. Klotho regulates the expression of FOXO1. (A) RT-PCR was performed to determine the expression 
levels of FOXO1 in HEK293 cells. GAPDH was used as an internal control. FOXO1 protein levels were analyzed using Western blot. (B) 
FOXO1 mRNA levels in HEK293 cells were assessed using real-time RT-PCR analysis. The expression levels were normalized to GAPDH. 
*p<0.05.
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Supplementary Figure S2. Metabolites identified in principle metabolic pathways in SAMP1/kl-/- and Hl156A-treated SAMP1/kl-
/- kidneys. Detected HMT Standard Metabolites are plotted on the pathway map. The bars/lines represent the relative areas covered by each 
metabolite in the SAMP1/kl+/+ (blue), SAMP1/kl-/- (red), HL156A-treated SAMP1/kl-/- kidney tissues (green). 
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Supplementary Figure S4. Tongue tissue sections labeled with von Kossa stain. Photomicrographs of tongue sections of 
SAMP1/kl-/- and HL156A- or nicotinamide (NAC)-treated SAMP1/kl-/- mice. 
Supplementary Figure S3. Comparison of the relative amounts of GSSG and GSH metabolites in SAMP1/kl-/- and 
HL156A-treated SAMP1/kl-/- mouse kidneys. Columns represent the relative areas, and numbers represent the ratios of the 
relative amounts of metabolites in SAMP1/kl-/- vs. SAMP1/kl+/+ or HL156A-treated SAMP1/kl-/- vs. SAMP1/kl-/- samples. 
